Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

blogs: 1 blog

policy: 1 policy source

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 36 Mendeley

Summary Blogs Policy documents Dimensions citations

So far, Altmetric has seen 1 blog post.

Innovative and Value-based Approaches to Confronting High Drug Prices

The Incidental Economist, 10 May 2018

Gilbert Benavidez is a Policy Analyst with Boston University’s School of Public Health. He tweets at @GBinsolidarity Research…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.